LBL-054 TDC / Leads Biolabs - LARVOL DELTA

LBL-054 TDC: A first-in-class CDH17 targeted T cell engager drug conjugate for the treatment of CDH17-positive gastrointestinal cancer (AACR 2026) - "Our results demonstrate that LBL-054 TDC combines the potent, direct killing of an ADC with the T-cell redirecting activity of a TCE both in vitro and in vivo while posing a lower cytokine release than a conventional TCE. It also exhibited good safety profiles in cynomolgus monkeys. Overall, LBL-054 TDC holds promise for treating gastrointestinal cancers with varying T-cell infiltration and CDH17 expression, potentially benefiting a broad patient population."

Gastrointestinal Cancer • Oncology • Solid Tumor • CDH17

LBL-054 TDC Poster Presentation (HKEXnews) - "...Abstracts accepted for presentation at the 2026 AACR Annual Meeting....In T cell-dependent cellular cytotoxicity (TDCC) assays, LBL-054 TDC induced potent cytotoxicity across varying effector-to-target ratios and CDH17 expression levels, with lower cytokine release compared to conventional TCEs. LBL-054 TDC also mediates potent bystander killing of CDH17-negative tumor cells without affecting T cells. In the MC38/hCDH17 syngeneic mouse model, LBL-054 TDC demonstrated superior anti-tumor efficacy compared to both TCE and ADC."

Preclinical • Solid Tumor